USP7 and myelodysplastic syndrome: In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion 33-35, our discovery that USP7 is a critical stabilizer of PU.1 suggests that targeted activation of the USP7-PU.1 axis could represent a novel therapeutic strategy.